|
|
Article: MedaSorb Technologies MSBT.OB Draws Closer to Completion of Human Clinical Trials.
- Article from:
- Blood Weekly
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TapeBeat.com, the news and research portal for the serious bio-tech investor in conjunction with the Farseers Group is proud to profile one of the most exciting up and coming biotech companies, MedaSorb Technologies (MSBT.OB), which is perfectly poised to realize exponential growth (see also TapeBeat.com).
MedaSorb Technologies is a medical device company that operates exclusively through its wholly owned subsidiary, CytoSorbents Inc. Their flagship medical device, the "CytoSorb™", is a patented blood purification device that uses state of the art resin technology to remove toxins from the blood, allowing the recirculation of clean blood back into the body. ...